Applications of the pharmacokinetic/pharmacodynamic (PK/PD) analysis of antimicrobial agents

Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy
Eduardo Asín-PrietoArantxazu Isla

Abstract

The alarming increase of resistance against multiple currently available antibiotics is leading to a rapid lose of treatment options against infectious diseases. Since the antibiotic resistance is partially due to a misuse or abuse of the antibiotics, this situation can be reverted when improving their use. One strategy is the optimization of the antimicrobial dosing regimens. In fact, inappropriate drug choice and suboptimal dosing are two major factors that should be considered because they lead to the emergence of drug resistance and consequently, poorer clinical outcomes. Pharmacokinetic/pharmacodynamic (PK/PD) analysis in combination with Monte Carlo simulation allows to optimize dosing regimens of the antibiotic agents in order to conserve their therapeutic value. Therefore, the aim of this review is to explain the basis of the PK/PD analysis and associated techniques, and provide a brief revision of the applications of PK/PD analysis from a therapeutic point-of-view. The establishment and reevaluation of clinical breakpoints is the sticking point in antibiotic therapy as the clinical use of the antibiotics depends on them. Two methodologies are described to establish the PK/PD breakpoints, which are a big part of the cli...Continue Reading

References

May 1, 1990·The Journal of Infectious Diseases·R N Greenberg, C A Benes
Mar 1, 1995·Antimicrobial Agents and Chemotherapy·D P NicolauR Quintiliani
Apr 25, 2001·International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity·U M HollensteinM Müller
May 1, 2001·Clinical Pharmacokinetics·A AminimanizaniR Jelliffe
Apr 30, 2002·International Journal of Antimicrobial Agents·D Andes, W A Craig
Apr 30, 2002·International Journal of Antimicrobial Agents·Ping LiuHartmut Derendorf
Dec 25, 2003·Antimicrobial Agents and Chemotherapy·Nasia SafdarW A Craig
Mar 20, 2004·Nature Reviews. Microbiology·George L Drusano
Mar 18, 2005·The Journal of Antimicrobial Chemotherapy·Johan W MoutonGeorge L Drusano
Nov 1, 2005·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Shigenobu MatsuzakiShosuke Imai
Jan 21, 2006·Critical Care Medicine·Jean-Louis VincentUNKNOWN Sepsis Occurrence in Acutely Ill Patients Investigators
Dec 23, 2006·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·D S BurgessJ H Jorgensen
Mar 14, 2007·Diagnostic Microbiology and Infectious Disease·C Andrew DeRykeDavid P Nicolau
Jul 17, 2007·Clinical Microbiology Reviews·John Turnidge, David L Paterson
Aug 19, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Sara K Olofsson, Otto Cars
Feb 26, 2008·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Kazuro IkawaHidemichi Suyama
Jul 16, 2008·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Kazuro IkawaTaijiro Sueda
Jul 16, 2008·Current Opinion in Pharmacology·Stephan SchmidtHartmut Derendorf
Aug 19, 2008·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Kazuro IkawaTaijiro Sueda
Aug 30, 2008·Antimicrobial Agents and Chemotherapy·G L DrusanoArnold Louie
Dec 17, 2009·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Kazuro IkawaTakao Yamanoue
Jan 23, 2010·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Kazuro IkawaMasao Kobayashi
Apr 14, 2010·Antimicrobial Agents and Chemotherapy·Mahesh N SamtaniPartha Nandy
Dec 2, 2010·The Journal of Antimicrobial Chemotherapy·Jason A RobertsJeffrey Lipman
Dec 15, 2010·Clinical Pharmacokinetics·Marta UlldemolinsJeffrey Lipman
Jan 15, 2011·Clinical Microbiology Reviews·Lynn L Silver
Feb 25, 2011·Bulletin of the World Health Organization·Theresa Braine
Mar 17, 2011·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Takashi DeguchiTetsuro Matsumoto
Mar 23, 2011·Obstetrics and Gynecology·Leo PevznerCharles E Edmiston
May 21, 2011·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·T KosakaN Fujita
Aug 13, 2011·Current Opinion in Pharmacology·Phillip J BergenRoger L Nation
Sep 14, 2011·Antimicrobial Agents and Chemotherapy·Takehito YamamotoHiroshi Suzuki

❮ Previous
Next ❯

Citations

Jan 20, 2016·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·A IslaA Rodríguez-Gascón
May 2, 2016·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·R Zachary ThompsonDavid S Burgess
Jul 16, 2016·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·O AsuphonP Sonthisombat
Oct 27, 2016·Biochemical Pharmacology·Çiğdem Yılmaz, Gülay Özcengiz
Feb 15, 2018·Clinical Pharmacokinetics·Idoia Bilbao-MeseguerMaría Ángeles Solinís
May 9, 2019·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Christine PeragineLesley Palmay
May 22, 2019·Antimicrobial Agents and Chemotherapy·Laura McEnteeWilliam Hope
Jul 25, 2019·Chinese Medical Journal·Jian Wang, Yuan-Lin Song
Jan 10, 2018·Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis·Colin LeeAndrew Simor
Dec 15, 2019·European Journal of Clinical Pharmacology·Shampa DasJianguo Li
Feb 23, 2020·Drug Metabolism Reviews·Neha MaharaoJyotika Varshney
Mar 12, 2020·Journal of Veterinary Pharmacology and Therapeutics·Gabriela A AlbarellosMaria F Landoni
Apr 11, 2020·Clinical Pharmacology and Therapeutics·Rasmus Jansson-LöfmarkJohan Gabrielsson
Aug 5, 2020·Journal of Veterinary Pharmacology and Therapeutics·Ehab A Abu-BashaNasir M Idkaidek
Sep 9, 2019·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·J W S CattrallA Kirby
Jul 28, 2017·Frontiers in Public Health·Stefanie Jane OliverJeanette E Ward
May 13, 2020·Antimicrobial Agents and Chemotherapy·L Herrera-HidalgoM V Gil-Navarro
Oct 12, 2018·Journal of Veterinary Pharmacology and Therapeutics·Maria Fabiana Landoni, Gabriela Alejandra Albarellos
Feb 5, 2019·Journal of Veterinary Pharmacology and Therapeutics·Jesús MendozaHector Sumano
Jul 15, 2020·Antibiotics·Iris H Chen, David P Nicolau
Oct 1, 2019·Journal of Veterinary Science·Wanhe LuoShuyu Xie
Nov 1, 2020·Journal of Veterinary Pharmacology and Therapeutics·Jose Julio De LucasManuel I San Andrés
Mar 10, 2020·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·R Díaz de León-OrtegaN Fotaki
Dec 15, 2020·Journal of Global Antimicrobial Resistance·Ghada El-Saeed Mashaly, Mervat El-Sayed Mashaly
Jul 9, 2020·Enfermedades infecciosas y microbiología clínica·Maitane Ibar-BariainAndrés Canut-Blasco

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Related Papers

International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases
Haiyan DongYalin Dong
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy
J W MoutonJohn Turnidge
Infectious Disease Clinics of North America
Ping Liu, Hartmut Derendorf
© 2022 Meta ULC. All rights reserved